
Roche has unveiled new Phase 3 data for its cancer immunotherapy Tecentriq (atezolizumab) in combination with carboplatin and etoposide chemotherapy …

Bristol-Myers Squibb will not attempt to bring its new combination hepatitis C treatment to the US market given the current …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

